Login to Your Account



Pfizer halts its PCSK9 program as industry seeks clarity on class

By Marie Powers
News Editor

Tuesday, November 1, 2016

After advancing its PCSK9 inhibitor, bococizumab, into a global phase III development program that included six lipid-lowering and two cardiovascular outcome trials, Pfizer Inc. blinked.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription